Literature DB >> 16231309

TORCH test for fetal medicine indications: only CMV is necessary in the United Kingdom.

Sherif A Abdel-Fattah1, Abha Bhat, Sebastian Illanes, Jose L Bartha, David Carrington.   

Abstract

OBJECTIVES: To review the indications and value of TORCH testing (toxoplasma, rubella, cytomegalovirus, herpes) for fetal medicine reasons.
METHODS: Analysis of all maternal and fetal TORCH tests requested from a busy Fetal Medicine Unit during nearly a 10-year period. The main ultrasound findings considered as possibly caused by congenital fetal infections were analysed. Pregnancy outcomes for cases with confirmed maternal or fetal infections were studied.
RESULTS: Four hundred and sixty-two maternal TORCH tests were performed. Of those, TORCH tests were also performed on fetal samples (amniotic fluid or fetal blood) in 67 cases. Fourteen fetal tests without maternal testing were identified, making the total number of patients tested 476. There were 11 cases of maternal CMV infection (2.3%), 10 cases of fetal CMV infection, and none of the other viruses. Indications for testing included fetal hyperechogenic bowel, hydrops, cerebral ventriculomegaly, echogenic foci, oligohydramnios, polyhydramnios, and IUGR. The most common findings to be actually associated with fetal infections were hyperechogenic bowel, ascites, cardiomegaly, and oligohydramnios. No cases were associated with polyhydramnious, while both IUGR and ventriculomegaly were always associated with other more relevant features.
CONCLUSION: In the United Kingdom, complete maternal TORCH testing because of fetal findings on detailed scans is often not necessary. Testing can be limited only to CMV, particularly since other infectious agents, including toxoplasmosis, are uncommon in the United Kingdom. More understanding of the relevance of the different ultrasound features to congenital infections is also important. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 16231309     DOI: 10.1002/pd.1242

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  7 in total

1.  Multiplex detection of IgM and IgG class antibodies to Toxoplasma gondii, rubella virus, and cytomegalovirus using a novel multiplex flow immunoassay.

Authors:  M J Binnicker; D J Jespersen; J A Harring
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

2.  Significance of isolated borderline ventriculomegaly.

Authors:  Katrin Tomic; Heidrun Schönberger; Peter Weber; Olav Lapaire; Gwendolin Manegold-Brauer
Journal:  Childs Nerv Syst       Date:  2019-05-12       Impact factor: 1.475

3.  Polyhydramnios: Causes, Diagnosis and Therapy.

Authors:  A Hamza; D Herr; E F Solomayer; G Meyberg-Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

4.  TORCH seroprevalence among patients attending Obstetric Care Clinic of Haydarpasa Training and Research Hospital affiliated to Association of Istanbul Northern Anatolia Public Hospitals.

Authors:  Onur Numan; Fisun Vural; Nurettin Aka; Murat Alpay; Ayse Deniz Erturk Coskun
Journal:  North Clin Istanb       Date:  2015-12-25

5.  Six-sigma and quality planning of TORCH tests in the Peruvian population: a single-center cross-sectional study.

Authors:  Jeel Moya-Salazar; Bianca M SantaMaria; Marcia M Moya-Salazar; Víctor Rojas-Zumaran; Karina Chicoma-Flores; Hans Contreras-Pulache
Journal:  BMC Res Notes       Date:  2022-01-11

6.  Comprehensive Assessment of Fetal Bilateral Ventriculomegaly Based on Genetic Disorders, Cytomegalovirus Infection, Extra Prenatal Imaging and Pregnancy Outcomes in a Tertiary Referral Center.

Authors:  Danhua Guo; Deqin He; Qingmei Shen; Na Lin; Shuqiong He; Yifang Dai; Ying Li; Liangpu Xu; Xiaoqing Wu
Journal:  Int J Gen Med       Date:  2021-11-05

7.  TORCH (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus) screening of small for gestational age and intrauterine growth restricted neonates: efficacy study in a single institute in Korea.

Authors:  Mi Hae Chung; Chan Ok Shin; Juyoung Lee
Journal:  Korean J Pediatr       Date:  2018-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.